Kari Clark
Interventional Cardiology · Stuart, FLNPI 1639535784
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 90.1% of the total across 191 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 24 manufacturers reported payments, led by Abbott at 38.2% of the total. Reporting peaked in 2023 at $2,107 and has fallen 60.3% since, to $836 in 2025. That places this record below the midpoint for interventional cardiology clinicians in FL, where the typical reported total is $7,973.
Across 191 payments — averaging $33.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$2K
- Medtronic$744
- Boston Scientific$602
- Abiomed$376
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$353
- Cardiovascular Systems Inc.$331
- plus $2K from 18 others
What the payments were for
- Travel & lodging$62310%
- Food & beverage$5,81890%
- Education$140%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 72 | $2,464 |
| Medtronic(2 entities) | 22 | $744 |
| Boston Scientific | 12 | $602 |
| Abiomed | 10 | $376 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 15 | $353 |
| Cardiovascular Systems Inc. | 23 | $331 |
| Edwards Lifesciences | 5 | $312 |
| Shockwave Medical, Inc | 4 | $295 |
| Atricure, Inc. | 2 | $189 |
| Biosense Webster, Inc. | 1 | $150 |
| Kestra Medical Technology Services, Inc. | 3 | $123 |
| Amgen | 4 | $71 |
| Heartflow, Inc. | 1 | $68 |
| AstraZeneca | 4 | $62 |
| Novartis | 2 | $54 |
| E.r. Squibb & Sons, L.L.C. | 2 | $48 |
| Harmony Biosciences LLC | 1 | $47 |
| Teleflex LLC | 1 | $33 |
| Cardinal Health 200 LLC | 2 | $28 |
| Novo Nordisk | 1 | $25 |
| Astellas Pharma US Inc | 1 | $22 |
| Penumbra, Inc. | 1 | $21 |
| Pfizer | 1 | $20 |
| Sanofi-aventis U.S. LLC | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AMPLATZER AMULET$614
- WATCHMAN Access System$398
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$253
- EPI-SENSE GUIDED COAGULATION SYSTEM WITH VISITRAX$171
- Confirm Rx$156
- NUVISION ICE CATHETER$150
- Micra$139
- LINQ II$139
- CARPENTIER-EDWARDS PHYSIO ANNULOPLASTY RING WITH HOLDER - MITRAL$133
- MitraClip System$124
- Impella$108
- Arctic Front$105
How this compares
$6,455 in reported general payments places this provider in the 40th percentile of 623 interventional cardiology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 181 | $220,183 |
| EntrestoSacubitril/Valsartan | 68 | $90,441 |
| XareltoRivaroxaban | 75 | $88,795 |
| Repatha SureclickEvolocumab | 47 | $41,568 |
| BrilintaTicagrelor | 31 | $33,664 |
| Atorvastatin Calcium | 282 | $3,407 |
| ClopidogrelClopidogrel Bisulfate | 139 | $2,346 |
| Prasugrel Hcl | 23 | $2,270 |
| Metoprolol Succinate | 129 | $1,630 |
| Carvedilol | 188 | $1,578 |
| Flecainide Acetate | 24 | $1,569 |
| Rosuvastatin Calcium | 126 | $1,387 |
| Ezetimibe | 39 | $1,326 |
| Amlodipine Besylate | 212 | $1,236 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 40 | $1,206 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $20 | $220,183181 claims |
| NovartisEntresto | $54 | $90,44168 claims |
| AstraZenecaBrilinta | $62 | $33,66431 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 623 interventional cardiology providers in Florida.
Other interventional cardiology in Stuart
- Arthur LeeGainesville$1.8M
- Santhosh MathewsBradenton$1.4M
- Siddharth WayangankarJacksonville$1.2M
- Patrick CambierTrinity$901K
- Zahid AminOrlando$635K
- Rohit AminPensacola$560K
- Eduardo de MarchenaMiami$498K
- Dominick AngiolilloJacksonville$387K
- Miguel DiazHialeah$383K
- Douglas EbersoleLakeland$373K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.